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http://dx.doi.org/10.1016/j.kjms.201Abstract Complete versus culprit-only revascularization in acute ST-elevation myocardial
infarction (STEMI) patients with multivessel disease is controversial. Current guidelines recom-
mend treatment of the culprit artery alone during the primary procedure. However, with
improvements in stent technique and with the use of new antiplatelet drugs (GP IIb/IIIa inhib-
itors), complete revascularization (CR) at an early stage is attracting increasing attention. We
conducted an English language search on Medline (PubMed database), Embase, and the Co-
chrane databases between January 1966 and January 2011, as well as a search on the China
National Knowledge Internet (1979eJanuary 2011), and the Chinese Biomedical Literature
Database (1978eJanuary 2011). Randomized controlled trials (RCTs) or non-RCTs that
compared the two strategies in patients with STEMI and multivessel disease (MVD) during
primary percutaneous coronary intervention (PCI) were included. Thirteen articles were
selected, 8240 patients in the CR group and 51,998 in the culprit-only revascularization group.
CR was associated with an increased short-term mortality [odds ratio (OR) Z 1.39, 95% confi-
dence interval (CI)Z (1.26, 1.53)], a long-term mortality [ORZ 1.35, 95% CIZ (1.09, 1.67)],
and an increased risk of renal failure [OR (95% CI) Z 1.24 (1.11, 1.38)] in patients with STEMI
and MVD at the primary procedure. In addition, CR did not reduce the rate of short-term major
adverse cardiac events [OR (95% CI) Z 1.52 (0.88, 2.61)] and remyocardial infarction
[OR Z 0.57, 95% CI Z (0.25, 1.29)]. However, CR was associated with a marked reduction in
the rate of revascularization [OR Z 0.45, 95% CI Z (0.27, 0.74)]. This analysis of currentardiology, West China Hospital, Sichuan University, Guoxuexiang 37 Hao, Chengdu 610041, China.
hotmail.com (Y. Chen).
hsiung Medical University. Published by Elsevier Taiwan LLC. All rights reserved.
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Complete versus culprit-only revascularization 141available data demonstrates that CR during primary PCI can put those patients with STEMI and
MVD at risk. To clarify this issue, large RCTs are needed.
Copyright ª 2013, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Approximately 30e60% of patients with ST-elevation
myocardial infarction (STEMI) have multivessel coronary
artery disease [1,2]. The optimal treatment strategy for
such patients at the primary procedure is controversial.
Revascularization of the nonculprit artery at an early stage
may increase the blood supply, and thus decrease the risk
of revascularization (re-VR) and remyocardial infarction
(re-MI), as well as improve cardiac function [3].
According to the guidelines of the American College of
Cardiology/American Heart Association (ACC/AHA) [4,5],
patients with STEMI and multivessel disease (MVD) should
be treated with culprit-vessel-only revascularization (COR),
following which the nonculprit vessel can be addressed in
an elective procedure. However, this recommendation is
merely based on expert consensus (level of evidence: C),
not on large-sample randomized controlled trials (RCTs). As
a result of improvements in stent technique and the use of
new antiplatelet drugs (GP IIb/IIIa inhibitors), complete
revascularization (CR) at an early stage attracts more and
more attention.
Several studies have demonstrated inconsistent outcome
for patients with CR at the primary stage [6e8]. To provide
a quantitative analysis of short- and long-term clinical
outcomes, we performed a meta-analysis of CR versus COR
at the primary procedure in patients with STEMI.
Materials and methods
Search strategy
We searched Medline (PubMed database), Embase, and
Cochrane databases for studies published between January
1966 and January 2011 using the terms “complete revas-
cularization,” “ST-elevated myocardial infarction,” and
“multivessel disease.” We then searched the China National
Knowledge Internet (CNKI, 1979eJanuary 2011) and the
Chinese Biomedical Literature Database (CBM,
1978eJanuary 2011) in Chinese. Studies were identified
manually, and cross-references were also explored.
Definition and endpoints
In our meta-analysis, we included RCTs and non-RCTs that
compared the two strategies in terms of prognosis in
patients with STEMI and MVD in primary percutaneous
coronary intervention (PCI). MVD was defined as the pres-
ence of 70% diameter stenosis (identified by angiography)
in two or more coronary arteries. CR was defined as the
procedure whereby the culprit and nonculprit vessels were
opened simultaneously in the primary procedure. COR wasdefined as the procedure whereby the culprit vessel alone
was opened in the primary procedure. Exclusion criteria
were as follows: (1) study population included patients with
rescue PCI; (2) patients undergoing CR not in a separate
group; and (3) no control group (COR). Primary endpoints
were short- and long-term mortality. Secondary endpoints
included rates of re-MI, re-VR, major adverse cardiac
events (MACE), and renal dysfunction post intervention. As
there is no unanimous definition of MACE, we used the
definition of the individual research paper.
Quality assessment
According to the “Cochrane Handbook for Systematic
Reviews of Interventions version 5.1.0,” quality assessment
of RCTs includes random sequence generation, allocation
concealment, blinding of participants and personnel,
blinding of outcome assessment, incomplete outcome data,
and selective reporting. Quality assessment of non-RCTs
(“Bracken MB” criterion, 1989) [9] includes four criteria:
how allocation occurred, any attempt to balance groups by
design, identification of prognostic factors, and case-mix
adjustment.
Statistics
Continuous variables are reported as the mean
value  standard deviation, and categorical variables are
presented as risk ratios and 95% confidence intervals (CIs).
Statistical analysis was performed using Review Manager
5.0. Heterogeneity was analyzed by means of standard Chi-
square tests, with p < 0.1 deemed statistically significant.
The random effects model was used when heterogeneity
was present, and sensitivity analysis was performed after
excluding the studies with huge heterogeneity.
Results
Thirteen studies were included in the final analysis, four
prospective studies including three RCTs [3,7,10,11] and
nine retrospective studies [6,8,12e18]. These 13 studies
included three RCTs [3,7,10] and two important conference
proceedings [17,18]. Details of the screening process for
studies are shown in Fig. 1. The quality assessment of
studies is shown in Tables 1 and 2.
Characteristics of eligible studies
In total, 60,238 patients were enrolled, 8240 in the CR
group and 51,998 in the COR group. Details of the studies’
characteristics are shown in Table 3. Compared with the
COR group, patients in the CR group had a lower rate of
Figure 1. Flow diagram of the reviewing process.
CBM Z Chinese Biomedical Literature Database;
CCRT Z Cochrane Controlled Trials Register; CNKI Z China
National Knowledge Internet; RCT Z randomized controlled
trial; STEMI Z ST-elevation myocardial infarction.
142 C. Lu et al.hypertension and hyperlipidemia. Two studies reported the
rate of cardiogenic shock, five studies excluded patients
with cardiogenic shock, and six trials reported the use of GP
IIb/IIIa inhibitors. There was a lower rate of usage of drug-
eluting and heparin-coated stents in the study conducted
by Di Mario et al. [10]. Table 4 lists the clinical outcomes of
the trials. Eleven studies reported short-time outcomes (in
hospital or at 30 days) and 10 studies reported long-term
outcomes, with a follow-up time of between 0.25 and 2.5




How allocation occurreda An
t
grou
Corpus (2004) Single-center database, not mentioned N
Khattab (2008) Single-center database, by date admission N
Varani (2008) Single-center database, by doctor N
Qarawani (2008) Single-center database, by doctor N
Cavender 2009 Multicenter registry data, not mentioned N
Hannan 2010 Multicenter registry data, not mentioned P
s
Toma 2010 Single-center database, not mentioned N
Dziewierz 2010 Multicenter registry data, not mentioned N
Non-RCT Z nonrandomized controlled trial.
a Most data were acquired from single-center database, and three
b Only one non-RCT used the propensity score match.
c All the studies reported the baseline characteristics with the exce
d Case-mix adjustment methods were not used in any trial.Short-term mortality
Across the entire 11 studies, 57,945 patients were enrolled,
49,970 in the COR group and 7975 in the CR group. No
heterogeneity was found among these trials (p Z 0.14,
I2 Z 32%); a fixed effects model was used. Compared with
COR, CR was associated with an increased in-hospital or 30-
day mortality [odds ratio (OR) Z 1.39, 95% CI Z (1.26,
1.53)] (Fig. 2). A similar result was found after excluding
the conference proceedings [OR Z 1.59, 95% CI Z (1.39,
1.81)].
Long-term mortality
A total of 10 studies were evaluated, 5212 patients in the
COR group where 378 patients died and 1681 patients in the
CR group with 147 deaths. Heterogeneity was found
(p Z 0.07, I2 Z 47%); a randomized model was used.
Patients treated with CR revealed a higher mortality rate in
comparison with those treated with COR (CR vs. COR: 8.7%
vs. 7.3%), and a significant difference was found between
the two strategies [OR (95% CI) Z 1.42 (1.01, 2.00),
p Z 0.04] (Fig. 3). A similar result was obtained following
the exclusion of conference abstracts [OR (95% CI) Z 1.60
(1.21, 2.11), p Z 0.18, I2 Z 32%].
Remyocardial infarction and revascularization
Fig. 4 demonstrates a comparison of the occurrence of re-
MI between the groups. Five articles reported on long-
term MI, 218 cases in the CR group and 544 cases in the
COR group. No heterogeneity was found between the trials
(p Z 0.87, I2 Z 0%), and therefore a fixed effects model
was used. The result showed that there was no significant
difference between the two groups [OR Z 0.57, 95%
CIZ (0.25, 1.29)]. Four trials reported the rate of re-VR; no
heterogeneity was found (p Z 0.13, I2 Z 47%), and a fixed








ot used Reported complications Not used
ot used Reported baseline characteristics Not used
ot used Reported age, gender, killip class,
anterior myocardial infarction
Not used
ot used Reported baseline characteristics Not used
ot used Reported baseline characteristics Not used
ropensity
core
Reported baseline characteristics Not used
ot used Reported baseline characteristics Not used
ot used Not reported Not used
trials reported the allocation method.
ption of the study of Dziewierz (2010).
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Not mentioned Not mentioned Not mentioned Complete Not mentioned
None of the three trials reported information regarding concealment, blinding method, or selective reporting.
Complete versus culprit-only revascularization 143that CR can reduce the rate of re-VR markedly [CR vs. COR:
16.1% vs. 30%, OR Z 0.45, 95% CI Z (0.27, 0.74),
p Z 0.002].
Renal dysfunction
Five studies reported on the rate of postoperative renal
failure. The CR group enrolled 7150 patients, of whom 473
had transient renal failure (6.6%). The COR group enrolled
48,188 patients, and renal failure occurred in 2155 patients
(4.5%). No heterogeneity was found (p Z 0.21, I2 Z 32%),
and a fixed effects model was used. The CR group had
higher rates of renal failure (6.6% vs. 4.5%), which indicates
that CR may increase the risk of renal failure after PCI in
STEMI patients with MVD [OR (95% CI) Z 1.23 (1.11, 1.37)]
(Fig. 5). There was no statistical difference after excluding
data from conference proceedings [OR Z 1.27, 95%
CI Z (0.99, 1.62)].
Short- and long-term MACE
Four articles were identified that referred to short-term
MACE, 175 in the CR group and 1123 in the COR group. No
heterogeneity was found (p Z 0.98, I2 Z 0%), and a fixed
effects model was used. The rates of short-term MACE were
11.4% in the CR group and 10.8% in the COR group. However,
there was no statistical difference between the groups [OR
(95% CI) Z 1.52 (0.88, 2.61)]. Five studies, a total of 762
patients, had data on long-term MACE. Heterogeneity was
found (p Z 0.08, I2 Z 52%), and a randomized model was
used. The result indicates that CR did not reduce the rate
of long-term MACE [OR Z 0.6, 95% CI Z (0.32, 1.11)].
Therefore, CR was not shown to reduce the rate of short- or
long-term MACE.
Short- and long-term mortality excluding
cardiogenic shock
Excluding patients with shock, six studies were included in
the meta-analysis. In short-term mortality analysis, five
studies [6e8,10,14] were included, 3415 patients in the CR
group and 23,775 in the COR group. No heterogeneity was
found (p Z 0.54, I2 Z 0%), and a fixed effects model was
used. The mortality rates were 3.3% in the CR group and
2.5% in the COR group. Compared with the COR group, theCR group was associated with an increased short-term
mortality rate [OR (95% CI) Z 1.28 (1.03, 1.59)]. In long-
term mortality analysis, five articles [3,6,7,10,14] were
included, 762 patients in the CR group and 673 in the COR
group. No heterogeneity was found (pZ 0.34, I2Z 0%), and
a fixed effects model was used. The mortality rates were
6.7% in the CR group and 6.4% in the COR group. There were
no significant differences between the groups in terms of
long-term mortality [OR Z 1.1, 95% CI Z (0.72, 1.70)].
There was no apparent publication bias among the trials
in terms of short-term mortality (Supplementary Figs. 1e4).
In addition, there was no apparent bias associated with
other outcome parameters.Discussion
The results of our analysis revealed an association between
CR and increased short-term mortality [OR Z 1.39, 95%
CI Z (1.26, 1.53)], increased long-term mortality
[OR Z 1.50, 95% CI Z (1.02, 2.18)], and increased risk of
renal failure [OR (95% CI) Z 1.24 (1.11, 1.38)] in patients
with STEMI and MVD, at the primary procedure. In addition,
CR did not appear to reduce the rate of short-term MACE
and re-MI; however, it can reduce the rate of re-VR
markedly.
MVD is an important predictor of long-term outcome in
STEMI patients. Patients with MVD have a lower ejection
fraction, a higher rate of re-MI and re-VR, and a worse
prognosis [19]. Theoretically, CR can maximally restore
myocardial blood supply, improve cardiac function,
decrease the rate of re-VR, and reduce medical costs. On
the other hand, CR may increase the risk of operation,
amount of contrast, and risk of renal failure. Much
controversy surrounds the two strategies. The ACC/AHA
does not suggest re-VR except for the culprit vessel. The
results of this meta-analysis support the current guidelines
for the management of patients with STEMI, which indicate
that the culprit vessel alone should be treated and that the
nonculprit vessel can be addressed in an elective
procedure.
Politi et al. [7] enrolled 214 patients, who did not have
cardiogenic shock, and divided them into three groups: CR,
COR, and staged revascularization (SR). A higher rate of
hospital death was observed in the COR group: 8.3% in COR
group, 3.1% in CR group, and 0% in SR group (p Z 0.037).


























Corpus (2004)a 26/354 NA NA NA NA NA NA NA NA NA
Carlo (2004) 51/17 63.5  12.4/ 88.2/84.6 11.5/41.2 41.2/52.9 36.5/58.8 66.6/81.0 Excluded 75/82.4 Heparin
coated65.3  7.4
Ochala (2004) 48/44 65  8.3/ 72.9/75.0 31.2/34.1 81.2/90.9 52.1/47.7 37.5/43.1 Excluded 51.5/50.7 NA
67  7.9
Khattab (2008) 28/45 69  12/ 75/78 7/16 79/80 75/82 36/40 3.6/4.4 36/44 0
65  13
Varani (2008)a 147/156 68.7  13/ 67/75 NA NA NA NA NA NA NA
69.8  13
Qarawani (2008) 95/25 66  3.2/ 65/61 12.5/16 13.6/16 37.8/40 61/60 Excluded 94.7/96 NA
67  3.7
Cavender (2009) 3134/25802 60(52-72)/ 71.5/72.1 24.7/23.4 56.5/58.6 60.4/63.2 63.2/64.8 13.8/10.3 NA NA
62(53-73)b
Politi (2010) 65/84 64.5  11.7 76.9/76.2 13.8/23.8 NA 49.2/59.5 NA Excluded 100/100 7.7/11.9
66.5  13.2
Hannan (2010) 503/503 NA 75.0/78.7 23.7/21.4 NA NA NA Excluded NA 56.7/61.1
Toma (2010) 217/1984 64(53,74)/
64(55,73)b
77.4/79.4 11.5/20 NA 47.5/55.6 38.2/39.9 NA 78.8/71.9 50.7/36.6
Dziewierz (2010)a 70/707 NA NA NA NA NA NA NA NA NA
Rahman (2010)c 578/1449 NA NA NA NA NA NA NA NA NA
Kugelmass (2010)c 3278/20828 NA 62.8/59.4 NA NA NA NA NA NA NA
COR Z culprit-vessel-only revascularization; CR Z complete revascularization; IIb/IIIa Z glycoprotein IIb/IIIa inhibitors; NA Z not available.
a Baseline characteristics were not described in the three trials.
b Ages in the two studies were reported as the median with 25th and 75th percentiles.









Table 4 Short- and long-term clinical outcomes in the included studies that compared CR versus COR.
First author
of studies

















Corpus (2004) 30 19/6.9 NA 23/14.7 1 19/12 19/12 NA 35/28
Carlo (2004) In hospital 1.9/0 NA 3.8/0 1 0/0 1.9/5.9 15.4/35.3 15.4/35.3
Ochala (2004)c NA NA NA NA 0.5 0/0 6.3/9.1 22.9/25 20.8/25
Khattab (2008) 30 3.6/4.5 NA 10.7/9.1 1 8/7 8/12 24/28 24/28
Varani (2008)d In hospital 8.2/3.6 NA NA NA NA NA NA NA
Qarawani 2008 In hospital 4.2/4 8.4/4 NA 1 9.4/8 NA NA NA
Cavender (2009)d In hospital 7.85/5.12 2.31/1.81 NA NA NA NA NA NA
Politi (2010) In hospital 3.1/8.3 1.5/3.6 NA 2.5 9.2/15.5 3.1/8.3 9.2/33.3 23.1/50.0
Hannan (2010) In hospital 3.4/2.0 NA NA 1 7.1/5.5 NA NA NA
Toma (2010)c NA NA NA NA 0.25 12.5/5.6 NA NA NA
Dziewierz (2010) 30 12.9/5.9 NA 12.9/9.2 1 15.7/8.1 NA NA NA
Rahman (2010) In hospital 5.0/4.4 18.9/18.5 NA 1 8.9/8.4 NA NA NA
Kugelmass (2010)d In hospital 7.5/6.18 8.8/6.8 NA NA NA NA NA NA
COR Z culprit-vessel-only revascularization; CR Z complete revascularization; MACE Z major adverse cardiac events; MI Z myocardial infarction; NA Z not available; re-
VR Z revascularization.
a Results of mortality, renal dysfunction incidence, and MACE incidence of studies that compared CR versus COR during hospitalization or
after 30-day follow-up.
b Results of mortality, MI, re-VR, and MACE of studies comparing CR versus COR over a long-term follow-up.
c Data on short-term outcomes were not available from these two trials.























Figure 2. Overall and stratified odds ratio for short-term mortality in patients treated with CR versus COR. Size of squares
corresponds to the weight of each study in the meta-analysis; lozenges indicate summary effect estimate. The vertical line
indicates an odds ratio of 1.0, equivalent to no difference between treatment groups. The diamond indicates that CR increased the
short-term mortality. CI Z confidence interval; COR Z culprit-vessel-only revascularization; CR Z complete revascularization;
RCT Z randomized controlled trial.
146 C. Lu et al.After a follow-up of 2.5 years, the COR group had a higher
rate of MACE, re-VR, and rehospitalization (p < 0.001).
However, there was no significant difference in re-MI
(p Z 0.412) and long-term mortality (COR vs. CR vs. SR:
15.5% vs. 9.2% vs. 6.2%, p Z 0.17). The study of Ochala
et al. [3] also excluded those with cardiac shock. Compare
with SR (two-staged PCI), CR (one-staged PCI) decreased
the rate of re-MI (6.3% vs. 9.1%), re-VR (9.2% vs. 33.3%), and
MACE (20.8% vs. 25%). However, there were no deaths.
Only two studies [8,11] reported the rate of cardiogenic
shock in this meta-analysis. Five trials excluded those with
cardiogenic shock. The proportion of cardiogenic shock was
5.3% in the CR group and 5.1% in the COR group. As a result
of these low percentages, conclusions of this meta-analysis
are not applicable generally to patients with cardiogenic
shock. In the analysis of those without cardiogenic shock,
the results showed that CR could increase short-term
mortality, but might not affect long-term mortality.
However, it is important to note that only three small-
sample-size trials had death events in terms of long-term
mortality. The test efficiency may be too low to discover
real differences between the groups.A large contrast volume has a deleterious effect on renal
function and prognosis in patients with STEMI. According to
the Marenzi et al. [20], larger contrast volume (>300 mL) is
associated with a higher rate of contrast-induced nephrop-
athy, [ORZ 2.80, 95% CIZ (1.17，6.68), pZ 0.02]. More-
over, patients who developed nephropathy had significantly
higher in-hospital mortality rates (31% vs. 0.6%, pZ 0.001).
In our analysis, the CR group had a greater contrast volume
compared with the COR group in four trials [3,7,8,11]. Cav-
ender et al. [8] found that the mean volume of contrast was
255 mL in the CR group and 200 mL in the COR group
(p < 0.01), while higher rates of renal failure were observed
in patients with CR (CR vs. COR: 2.31% vs. 1.81%, pZ 0.09).
Sethi et al. [21], who compared the two strategies,
found that there was no significant difference in short- and
long-term mortality, MACE, and re-PCI. The authors defined
CR as “during primary procedure or index hospitalization,”
and thus their included studies were different from ours. In
addition, patients who received staged PCI may have
a better outcome compared with the CR or the COR group
[7]. As a result, the CR group, which included staged PCI,
may have a better prognosis.
Figure 3. Overall and stratified odds ratio for long-term mortality in patients treated with CR versus COR. The diamond indicates
that CR increased the long-term mortality. CIZ confidence interval; CORZ culprit-vessel-only revascularization; CRZ complete
revascularization; RCT Z randomized controlled trial.
Complete versus culprit-only revascularization 147The meta-analysis by Navarese et al. [22] showed similar
outcomesbetween thegroups, apart fromadecreased re-PCI
rate in the CR group. The meta-analysis included only 10
articles, and two studies [23,24] did not match our inclusionFigure 4. Overall and stratified odds ratio for long-term myocard
on the vertical line indicate no significant difference between the t
revascularization; CR Z complete revascularization; RCT Z randocriteria. In addition, we included two large sample trials
[6,7]. Of note is the higher short- and long-term mortality
observed in the CR group in the study of Navarese et al.,
although no statistical significant difference was found.ial infarction in patients treated with CR versus COR. Lozenges
wo groups. CIZ confidence interval; CORZ culprit-vessel-only
mized controlled trial.
Figure 5. Analysis for the incidence of renal failure after treatment with CR or COR. Lozenge on the right side of vertical line
indicates that culprit-only revascularization may increase the risk of renal failure. CIZ confidence interval; CORZ culprit-vessel-
only revascularization; CR Z complete revascularization.
148 C. Lu et al.Study limitations
Our meta-analysis included 13 studies, three of which were
RCTs, and all of which were small-sample trials. Only one
non-RCT used the propensity score match [6]. Overall,
comparability between groups was low, and many potential
confounding factors might exist. This might affect the
strength of evidence presented by this meta-analysis. In
addition, the follow-up time was limited, with two RCTs
following patients for 0.5 year [3] and 1 year [10], respec-
tively, and there were no deaths in the two RCTs. To date,
the exact long-term clinical outcomes have not been clear
from the available data. Toma et al. [15] reported only on
the 3-month outcome. In addition, in order to make the
data collection as complete as possible, we included two
important conference proceedings with incomplete data.
However, a similar statistical result was obtained after they
were excluded, with the exception of the result for renal
dysfunction. Moreover, in our meta-analysis, the COR group
included staged PCI, but the definition was not consistent in
some trials. Politi et al. [7] separated staged PCI into
a distinct group. As a result, the differences between the
two groups might have been exaggerated in our analysis.
In summary, our analysis shows that CR as a strategy in
primary PCI for patients with STEMI and MVD potentially
increases the risk of short- and long-term mortality, even
though there is a reduction in the re-VR rate. Therefore,
COR may be the treatment of choice according to currently
available evidence.
Appendix. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/
j.kjms.2012.08.024
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